Middle East & Africa Ophthalmology Devices Market Forecast to 2031 - Regional Analysis by Product, Application and End User
November 25, 2024 07:27 ET
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Middle East & Africa Ophthalmology Devices Market Forecast to 2031 - Regional Analysis - by Product, Application, and End User" report has been...
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
November 25, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting...
Ophthalmology Devices Market Analysis Report 2025-2030: Industry Trends, Market Shares and Competitive Strategies
November 21, 2024 04:57 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmology Devices Market by Devices, Application - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.The...
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
November 20, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
November 19, 2024 08:00 ET
|
SpyGlass Pharma, Inc.
SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
November 19, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
November 08, 2024 06:45 ET
|
Ocugen
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in...
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
November 07, 2024 09:05 ET
|
Clearside Biomedical, Inc.
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space...
Ocugen Secures $30 Million in Debt Funding
November 07, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Pacific Eye Associates Selects Nextech
November 05, 2024 09:00 ET
|
Nextech Systems, Inc.
Nextech's ophthalmic platform has been selected by Pacific Eye Associates to automate operational and clinical workflows, and increase speed to revenue.